Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Circulation

• Publication date

  2011-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.111.042523PMID 21986285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coronary Heart Disease in Familial Hypercholesterolemia

  2012cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2011cited by this paper
• A prospective natural-history study of coronary atherosclerosis.

  2011cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

  2011cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cited by this paper
• Lipoprotein apheresis

  2010cited by this paper
• Other therapies for reducing low-density lipoprotein cholesterol: medications in development.

  2009cited by this paper
• A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.

  2008cited by this paper
• Vascular Calcifications in Homozygote Familial Hypercholesterolemia

  2008cited by this paper
• Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

  2008cited by this paper
• Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

  2008cited by this paper
• Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype.

  2007cited by this paper
• Lowering LDL--Not Only How Low, But How Long?

  2006cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.

  2003cited by this paper
• Statins in homozygous familial hypercholesterolemia

  2002cited by this paper
• Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia

  2002cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• The Molecular Mechanism for the Genetic Disorder Familial Defective Apolipoprotein B100*

  2001cited by this paper
• Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis.

  2001cited by this paper
• Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass.

  2000cited by this paper
• Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.

  2000cited by this paper
• Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

  1998cited by this paper
• Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia

  1998cited by this paper
• Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.

  1997cited by this paper
• Nonradioactive multiplex PCR screening strategy for the simultaneous detection of multiple low-density lipoprotein receptor gene mutations.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Identification and properties of the proline664-leucine mutant LDL receptor in South Africans of Indian origin.

  1992cited by this paper
• Three mutations that cause familial hypercholesterolemia in Afrikaners identified--a milestone in South African medicine.

  1989cited by this paper
• A host of hypercholesterolaemic homozygotes in South Africa.

  1980cited by this paper
• Failure of complete bile diversion and oral bile acid therapy in the treatment of homozygous familial hypercholesterolemia.

  1977cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• RISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATES

  1969cited by this paper
• Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states.

  1969cited by this paper

• The High Price of Interrupted Follow‐Up: Catastrophic Progression of Homozygous Familial Hypercholesterolemia—A Case Report and Literature Review

  2026cites this paper
• Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype.

  2026cites this paper
• Clinical Management of Dyslipidemia in Infants and Toddlers

  2025cites this paper
• Treatment of Homozygous Familial Hypercholesterolemia

  2025cites this paper
• Genetic Testing for Children with Familial Hypercholesterolemia.

  2025cites this paper
• Homozygous familial hypercholesterolemia: New therapeutic approach and a call for action!

  2025cites this paper
• Familial Hypercholesterolemia

  2025cites this paper
• One Shock, Not One Cure: Electroporation Reveals Disease-Specific Constraints in Hepatocyte Gene Editing Therapy

  2025cites this paper
• Early-onset valvular dysfunction as a presentation of familial hypercholesterolemia due to LDL receptor mutation and response to LDL apheresis

  2025cites this paper
• Imputation of untreated LDL-C in treated subjects with homozygous familial hypercholesterolaemia: An international collaboration.

  2025cites this paper
• Lomitapide for the treatment of pediatric homozygous familial hypercholesterolemia

  2025cites this paper
• Diagnostic and Therapeutic Challenges of Homozygous and Severe Heterozygous Familial Hypercholesterolemia from Clinical Aspect—A Single-Center Study

  2025cites this paper
• Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial.

  2025cites this paper
• Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.

  2025cites this paper
• Safe Continuation of Apheresis during Pregnancy using the Double-Filtration Plasmapheresis Thermo Mode in a Pregnant Female with Familial Hypercholesterolemia: A Case Report

  2025cites this paper
• Severe hypercholesterolemia in a pediatric cohort: Familial homozygous and autosomal recessive hypercholesterolemia.

  2025cites this paper
• Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over 10 years of efficacy and safety data.

  2025cites this paper
• Universal Pediatric Cholesterol Screening: The Time Has Come!

  2024cites this paper
• Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary.

  2024cites this paper
• Safety assessment of ezetimibe: real-world adverse event analysis from the FAERS database

  2024cites this paper
• Extreme LDL-C concentration is associated with increased cardiovascular disease in women with homozygous familial hypercholesterolemia.

  2024cites this paper
• JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease.

  2024cites this paper
• Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.

  2024cites this paper
• The therapeutic effect of liver transplantation in 14 children with homozygous familial hypercholesterolemia: a prospective cohort: Liver transplant for familial hypercholesterolemia.

  2024cites this paper
• It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States

  2024cites this paper
• Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia

  2024cites this paper
• The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis

  2024cites this paper
• Is Liver Transplantation Alone an Effective Treatment for Homozygotic Familial Hypercholesterolemia in Children?

  2024cites this paper
• Homozygous Familial Hypercholesterolemia Treatment: New Developments

  2024cites this paper
• Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA).

  2024cites this paper
• Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study.

  2024cites this paper
• Identification of a mechanism promoting mitochondrial sterol accumulation during myocardial ischemia–reperfusion: role of TSPO and STAR

  2024cites this paper
• Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment

  2023cites this paper
• Familial Hypercholesterolemia: From Clinical Suspicion to Novel Treatments

  2023cites this paper
• Paradoxical Findings in Homozygous Familial Hypercholesterolemia in Japan

  2023cites this paper
• Liver transplantation for homozygous familial hypercholesterolemia: Cure for a genetic disease?

  2023cites this paper
• Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia

  2023influential citation
• Homozygous Familial Hypercholesterolemia in Canada

  2023cites this paper
• Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

  2023cites this paper
• The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies.

  2023cites this paper
• Modelling the potential long-term survival benefit of evinacumab treatment versus standard of care in patients with homozygous familial hypercholesterolemia.

  2023cites this paper
• Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?

  2023cites this paper
• Recent advances in the management and implementation of care for familial hypercholesterolaemia.

  2023cites this paper
• Homozygous Familial Hypercholesterolemia

  2023cites this paper
• In silico discovery of food-derived phytochemicals against asialoglycoprotein receptor 1 for treatment of hypercholesterolemia: Pharmacophore modeling, molecular docking and molecular dynamics simulation approach.

  2023cites this paper
• Metabolic systems approaches update molecular insights of clinical phenotypes and cardiovascular risk in patients with homozygous familial hypercholesterolemia

  2023cites this paper
• Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus Seminar 1/3.

  2023cites this paper
• Gene Therapy for Paediatric Homozygous Familial Hypercholesterolaemia.

  2023cites this paper
• Disparities in statin prescription among patients with severe hypercholesterolemia in an integrated healthcare system.

  2023cites this paper
• Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry

  2023cites this paper
• Opportunistic Genetic Screening for Familial Hypercholesterolemia in Heart Transplant Patients

  2023cites this paper
• Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022

  2023cites this paper
• Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9

  2023cites this paper
• Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

  2023cites this paper
• Clinical Evaluation of Patients with Genetically Confirmed Familial Hypercholesterolemia

  2023cites this paper
• MODERN APPROACHES IN THE TREATMENT OF DYSLIPIDEMIA AND FUTURE PERSPECTIVES

  2023cites this paper
• Familial hypercholesterolaemia and emerging therapeutics

  2023cites this paper
• Prevalence and Treatment of Familial Hypercholesterolemia and Severe Hypercholesterolemia in Older Adults in Ontario, Canada

  2022cites this paper
• New algorithms for treating homozygous familial hypercholesterolemia

  2022cites this paper
• Introducing Personalized Medicine Into Pediatric Homozygous Familial Hypercholesterolemia Care.

  2022cites this paper
• Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis

  2022cites this paper
• Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review.

  2022cites this paper
• New Trends and Therapies for Familial Hypercholesterolemia

  2022cites this paper
• Treatment of hypercholesterolaemia to improve cardiovascular disease risk in South Africa

  2022cites this paper
• Efficacy and Safety of Lomitapide in Homozygous Familial Hypercholesterolaemia: A Systematic Review

  2022cites this paper
• Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome.

  2022cites this paper
• Homozygous familial hypercholesterolemia with cutaneous xanthomas in a child

  2022cites this paper
• Difficult Journey to Find the Best Treatment for Homozygous Familial Hypercholesterolemia: Case Report

  2022cites this paper
• Current Treatment Options in Homozygous Familial Hypercholesterolemia

  2022cites this paper
• Advancements in the Treatment of Homozygous Familial Hypercholesterolemia

  2022cites this paper
• Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience

  2022cites this paper
• Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia

  2022cites this paper
• LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective

  2021cites this paper
• Lipoprotein metabolism in familial hypercholesterolemia

  2021cites this paper
• Existing and emerging therapies for the treatment of familial hypercholesterolemia

  2021cites this paper
• Pharmacotherapy in Familial Hypercholesterolemia- Current State and Emerging Paradigms.

  2021cites this paper
• Sustained low‐density lipoprotein‐cholesterol <70 mg/dl is associated with improved cardiovascular outcomes in the clinical setting

  2021cites this paper
• EFFICACY AND SAFETY OF LOMITAPIDE IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: THE PAN-EUROPEAN RETROSPECTIVE OBSERVATIONAL STUDY.

  2021cites this paper
• New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia.

  2021cites this paper
• Familial homozygous hypercholesterolemia in children: early diagnosis and treatment

  2021cites this paper
• Health-related quality of life in homozygous familial hypercholesterolemia: A systematic review and meta-analysis.

  2021cites this paper
• Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry

  2021cites this paper
• Comparison of The Two Lipoprotein Apheresis Methods in The Treatment of Familial Hypercholesterolemia

  2021cites this paper
• Familial Hypercholesterolemia: Global Burden and Approaches

  2021cites this paper
• Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents

  2021cites this paper
• Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey

  2021cites this paper
• Vascular access for lipid apheresis: a challenge in young children with homozygous familial hypercholesterolemia

  2021cites this paper
• Antisense technology: an overview and prospectus

  2021cites this paper
• Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting

  2021cites this paper
• Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis.

  2021cites this paper
• Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia

  2021cites this paper
• Use of apheresis in the age of new therapies for familial hypercholesterolaemia

  2021cites this paper
• Management of Homozygous Familial Hypercholesterolemia

  2020cites this paper
• Registre national de l’hypercholestérolémie familiale : pourquoi et comment ?

  2020cites this paper
• Calcified Aortic Valve Disease in Patients With Familial Hypercholesterolemia.

  2020cites this paper
• Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia

  2020cites this paper
• Successful pharmacological management of a child with compound heterozygous familial hypercholesterolemia and review of the recent literature.

  2020cites this paper
• Antisense Drug Discovery and Development Technology Considered in a Pharmacological Context.

  2020cites this paper
• The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia

  2020cites this paper
• Autosomal recessive hypercholesterolemia in a kindred of Syrian ancestry.

  2020cites this paper